International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 322-332 , April 2010

Antibiotic resistance of bacterial biofilms

  • Niels Høiby

      Affiliations

    • Department of Clinical Microbiology 9301, Juliane Mariesvej 22, Rigshospitalet, 2100 Copenhagen, Denmark
    • Department of Bacteriology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 3545 7788; fax: +45 3545 6412.
    • ,
  • Thomas Bjarnsholt

      Affiliations

    • Department of Clinical Microbiology 9301, Juliane Mariesvej 22, Rigshospitalet, 2100 Copenhagen, Denmark
    • Department of Bacteriology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
    • ,
  • Michael Givskov

      Affiliations

    • Department of Bacteriology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
    • ,
  • Søren Molin

      Affiliations

    • BioCentrum, Danish Technical University, Lyngby, Denmark
    • ,
  • Oana Ciofu

      Affiliations

    • Department of Bacteriology, Institute of International Health, Immunology and Microbiology, University of Copenhagen, Denmark

Received 13 December 2009 ,Accepted 15 December 2009.

References 

  1. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest. 2003;112:1466–1477
  2. Bjarnsholt T, Jensen PØ, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol. 2009;44:547–558
  3. Kolenbrander PE, Palmer RJ. Human oral bacterial biofilms. In:  Ghannoum MA,  O’Toole GA editor. Microbial biofilms. Washington, DC: ASM Press; 2004;
  4. Høiby N, Döring G, Schiøtz PO. The role of immune complexes in the pathogenesis of bacterial infections. Annu Rev Microbiol. 1986;40:29–53
  5. Hall-Stoodley L, Hu FZ, Gieseke A, Nistico A, Nguyen L, Hayes J, et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA. 2006;296:202–211
  6. Sanderson AR, Leid JG, Hunsaker D. Bacterial biofilms on the sinus mucosa of human subjects with chronic rhinosinusitis. Laryngoscope. 2006;116:1121–1126
  7. Gristina AG, Oga M, Webb LX, Hobgood CD. Adherent bacterial colonization in the pathogenesis of osteomyelitis. Science. 1985;228:990–993
  8. Trampuz A, Zimmerli W. Prostetic joint infections: update in diagnosis and treatment. Swiss Med Wkly. 2005;135:243–251
  9. Del Pozo JL, Patel R. Infection associated with prostetic joints. N Engl J Med. 2009;361:787–794
  10. Taconelli E, Smith G, Hieke K, Lafuma A, Bastide P. Epidemiology, medical outcomes and costs of catheter-related bloodstream infection in intensive care units of four European countries: litterature- and registry-based estimates. J Hosp Infect. 2009;72:97–103
  11. Kirketerp-Møller K, Jensen PØ, Fazli M, Madsen KG, Pedersen J, Moser C, et al. Distribution, and ecology of bacteria in chronic wounds. J Clin Microbiol. 2008;46:2717–2722
  12. Bjarnsholt T, Kirketerp-Møller K, Jensen PØ, Madsen KG, Phipps R, Krogfelt K, et al. Why chronic wounds won’t heal: a novel hypothesis. Wound Repair Regen. 2008;16:2–10
  13. Høiby N, Johansen HK, Ciofu O, Jensen PØ, Bjarnsholt T, Givskov M. Foreign body infections—biofilms and quorum sensing. Ugeskr Laeger. 2007;169:4163–4166[in Danish]
  14. Wingender J, Strathmann M, Rode A, Leis A, Flemming HC. Isolation and biochemical characterization of extracellular polymeric substances from Pseudomonas aeruginosa. Methods Enzymol. 2001;336:302–314
  15. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295:1487
  16. Sternberg C, Christensen BB, Johansen T, Nielsen AT, Andersen JB, Givskov M, et al. Distribution of bacterial growth activity in flow-chamber biofilms. Appl Environ Microbiol. 1999;65:4108–4117
  17. Klausen M, Heydorn A, Ragas P, Lambertsen L, Aaes-Jorgensen A, Molin S, et al. Biofilm formation by Pseudomonas aeruginosa wild type, flagella and type IV pili mutants. Mol Microbiol. 2003;48:1511–1524
  18. Heydorn A, Ersboll B, Kato J, Hentzer M, Parsek MR, Tolker-Nielsen T, et al. Statistical analysis of Pseudomonas aeruginosa biofilm development: impact of mutations in genes involved in twitching motility, cell-to-cell signaling, and stationary-phase sigma factor expression. Appl Environ Microbiol. 2002;68:2008–2017
  19. Givskov M. Jamming the command language of bacteria: a new approach to the control of bacterial infections [Doctoral thesis]. Danish Technical University; 2005.
  20. Marshall KC. Biofilms: an overview of bacterial adhesion, activity, and control at surfaces. ASM News. 1992;58:202–207
  21. Webb JS, Thompson LS, James S, Charlton T, Tolker-Nielsen T, Koch B, et al. Cell death in Pseudomonas aeruginosa biofilm development. J Bacteriol. 2003;185:4585–4592
  22. Kobayashi N, Bauer TW, Tuohy MJ, Fujishiro T, Procop GW. Brief ultrasonication improves detection of biofilm-formative bacteria around a metal implant. Clin Orthop Relat Res. 2007;475:210–213
  23. Anwar H, Costerton JW. Enhanced activity of combination of tobramycin and piperacillin for eradication of sessile biofilm cells of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1990;34:1666–1671
  24. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol. 2004;42:1915–1922
  25. Bjarnsholt T, Kirketerp-Møller K, Kristiansen S, Phipps R, Nielsen AK, Jensen PØ, et al. Silver against Pseudomonas aeruginosa biofilms. APMIS. 2007;115:921–928
  26. Anwar H, Dasgupta MK, Costerton JW. Testing the susceptibility of bacteria in biofilms to antibacterial agents. Antimicrob Agents Chemother. 1990;34:2043–2046
  27. Domingue G, Ellis B, Dasgupta M, Costerton JW. Testing antimicrobial susceptibilities of adherent bacteria by a method that incorporates guidelines of the National Committee for Clinical Laboratory Standards. J Clin Microbiol. 1994;32:2564–2568
  28. Costerton JW, Lewandowski Z, Caldwell DE, Korber DR, Lappinscott HM. Microbial biofilms. Annu Rev Microbiol. 1995;49:711–745
  29. Werner E, Roe F, Bugnicourt A, Franklin MJ, Heydorn A, Molin S, et al. Stratified growth in Pseudomonas aeruginosa biofilms. Appl Environ Microbiol. 2004;70:6188–6196
  30. Keren I, Kaldalu N, Spoering A, Wang YP, Lewis K. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett. 2004;230:13–18
  31. Yang L, Haagensen JAJ, Jelsbak L, Johansen HK, Sternberg C, Høiby N, et al. In situ growth rates and biofilm development of Pseudomonas aeruginosa populations in chronic lung infection. J Bacteriol. 2008;190:2767–2776
  32. Driffield K, Miller K, Bostock M, O’Neill AJ, Chopra I. Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother. 2008;61:1053–1056
  33. Molin S, Tolker-Nielsen T. Gene transfer occurs with enhanced efficiency in biofilms and induces enhanced stabilisation of the biofilm structure. Curr Opin Biotechnol. 2003;14:255–261
  34. Høiby N, Johansen HK, Moser C, Song ZJ, Ciofu O, Kharazmi A. Pseudomonas aeruginosa and the biofilm mode of growth. Microbes Infect. 2001;3:1–13
  35. Oliver A, Canton R, Campo P, Baquero F, Blazquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000;288:1251–1253
  36. Ciofu O, Riis B, Pressler T, Poulsen HE, Høiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother. 2005;49:2276–2282
  37. Oliver A, Sanchez JM, Blazquez J. Characterization of the GO system of Pseudomonas aeruginosa. FEMS Microbiol Lett. 2002;217:31–35
  38. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother. 2009;53:2483–2491
  39. Macia MD, Blanquer D, Togores B, Sauleda J, Perez JL, Oliver A. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother. 2005;49:3382–3386
  40. Hassett DJ, Ma JF, Elkins JG, McDermott TR, Ochsner UA, West SEH, et al. Quorum sensing in Pseudomonas aeruginosa controls expression of catalase and superoxide dismutase genes and mediates biofilm susceptibility to hydrogen peroxide. Mol Microbiol. 1999;34:1082–1093
  41. Mai-Prochnow A, Lucas-Elio P, Egan S, Thomas T, Webb J, Sanchez-Amat A, et al. Hydrogen peroxide linked to lysine oxidase activity facilitates biofilm differentiation and dispersal in several Gram-negative bacteria. J Bacteriol. 2008;190:5493–5501
  42. Conibear TC, Collins SL, Webb JS. Role of mutation in Pseudomonas aeruginosa biofilm development. PLoS One. 2009;14:e6289
  43. Boles BR, Singh PK. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA. 2008;105:12503–12508
  44. Kolpen M, Hansen CR, Bjarnsholt T, Moser C, Christensen LD, van Gennip M, et al. Polymorphonuclear leucocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax. 2010;65:57–62
  45. Ciofu O, Giwercman B, Pedersen SS, Hoiby N. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS. 1994;102:674–680
  46. Ciofu O. Pseudomonas aeruginosa chromosomal β-lactamase in patients with cystic fibrosis and chronic lung infection—mechanism of antibiotic resistance and target of the humoral immune response. APMIS. 2003;111:4–47
  47. Jalal S, Ciofu O, Høiby N, Gotoh N, Wretlind B. Molecular mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother. 2000;44:710–712[Erratum in: Antimicrob Agents Chemother 2000;44:1410]
  48. Islam S, Oh H, Jalal S, Ciofu O, Høiby N, Wretlind B. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Clin Microbiol Infect. 2009;15:60–66
  49. Johansen HK, Moskowitz SM, Ciofu O, Pressler T, Høiby N. Spread of colistin-resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros. 2008;7:391–397
  50. Giwercman B, Lambert PA, Rosdahl VT, Shand GH, Hoiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother. 1990;26:247–259
  51. Nakae T, Nakajima A, Ono T, Saito K, Yoneyama H. Resistance to β-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and β-lactamase. Antimicrob Agents Chemother. 1999;43:1301–1303
  52. Bagge N, Ciofu O, Hentzer M, Campbell JIA, Givskov M, Hoiby N. Constitutive high expression of chromosomal β-lactamase in Pseudomonas aeruginosa caused by a new insertion sequence (IS1669) located in ampD. Antimicrob Agents Chemother. 2002;46:3406–3411
  53. de Beer D, Stoodley P, Lewandowski Z. Measurement of local diffusion coefficients in biofilms by microinjection and confocal microscopy. Biotechnol Bioeng. 1997;53:151–158
  54. Dibdin GH, Assinder SJ, Nichols WW, Lambert PA. Mathematical model of β-lactam penetration into a biofilm of Pseudomonas aeruginosa while undergoing simultaneous inactivation by released β-lactamases. J Antimicrob Chemother. 1996;38:757–769
  55. Ciofu O, Beveridge TJ, Kadurugamuwa J, Walther-Rasmussen J, Hoiby N. Chromosomal β-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa. J Antimicrob Chemother. 2000;45:9–13
  56. Giwercman B, Jensen ET, Hoiby N, Kharazmi A, Costerton JW. Induction of β-lactamase production in Pseudomonas aeruginosa biofilm. Antimicrob Agents Chemother. 1991;35:1008–1010
  57. Nichols WW, Evans MJ, Slack MP, Walmsley HL. The penetration of antibiotics into aggregates of mucoid and non-mucoid Pseudomonas aeruginosa. J Gen Microbiol. 1989;135:1291–1303
  58. Giwercman B, Meyer C, Lambert PA, Reinert C, Hoiby N. High-level β-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment. Antimicrob Agents Chemother. 1992;36:71–76
  59. Bagge N, Hentzer M, Andersen JB, Ciofu O, Givskov M, Hoiby N. Dynamics and spatial distribution of β-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother. 2004;48:1168–1174
  60. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J Clin Microbiol. 2005;43:5085–5090
  61. Ciofu O, Høiby N. Cystic fibrosis—coping with resistance. In:  Gould I,  van der Meer J editor. Antibiotic policies—fighting resistance. New York, NY: Springer Verlag; 2007;p. 149–174
  62. Bagge N, Schuster M, Hentzer M, Ciofu O, Givskov M, Greenberg EP, et al. Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and β-lactamase and alginate production. Antimicrob Agents Chemother. 2004;48:1175–1187
  63. Wood LF, Leech AJ, Ohman DE. Cell wall-inhibitory antibiotics activate the alginate biosynthesis operon in Pseudomonas aeruginosa: roles of sigma (AlgT) and the AlgW and Prc proteases. Mol Microbiol. 2006;62:412–426
  64. Dunne WM. Effects of subinhibitory concentrations of vancomycin or cefamandole on biofilm production by coagulase-negative staphylococci. Antimicrob Agents Chemother. 1990;34:390–393
  65. Permin H, Koch C, Høiby N, Christensen HO, Møller AF, Møller S. Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. J Antimicrob Chemother. 1983;12(Suppl A):313–323
  66. Anwar H, Strap JL, Costerton JW. Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy. Antimicrob Agents Chemother. 1992;36:1347–1351
  67. Levy J, Smith AL, Kenny MA, Ramsey B, Schoenknecht FD. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: comparison with activity in serum. J Infect Dis. 1983;148:1069–1076
  68. Hunt BE, Weber A, Berger A, Ramsey B, Smith AL. Macromolecular mechanisms of sputum inhibition of tobramycin activity. Antimicrob Agents Chemother. 1995;39:34–39
  69. Walters MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother. 2003;47:317–323
  70. Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;64:317–325
  71. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the prm and mexAB-oprM genes. Mol Microbiol. 2008;68:223–240
  72. Haagensen J, Klausen M, Ernst RK, Miller SI, Folkesson A, Tolker-Nielsen T, et al. Differentiation and distribution of colistin- and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol. 2007;189:28–37
  73. Hansen CR, Pressler T, Høiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008;7:523–530
  74. Bjarnsholt T, Jensen P-Ø, Burmølle M, Hentzer M, Haagensen JAJ, Hougen HP, et al. Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent. Microbiology. 2005;151:373–383
  75. Greenberg EP. Quorum sensing in Gram-negative bacteria. ASM News. 1997;63:371–377
  76. Lindum PW, Anthoni U, Christophersen C, Eberl L, Molin S, Givskov M. N-acyl-l-homoserine lactone autoinducers control production of an extracellular lipopeptide biosurfactant required for swarming motility of Serratia liquefaciens MG1. J Bacteriol. 1998;180:6384–6388
  77. Williams P, Camara M, Hardman A, Swift S, Milton D, Hope VJ, et al. Quorum sensing and the population-dependent control of virulence. Philos Trans R Soc Lond B Biol Sci. 2000;355:667–680
  78. Bjarnsholt T, Givskov M. The role of quorum sensing in the pathogenicity of the cunning aggressor Pseudomonas aeruginosa. Anal Bioanal Chem. 2007;387:409–414
  79. Jensen PØ, Bjarnsholt T, Phipps R, Rasmussen TB, Calum H, Christoffersen L, et al. Rapid necrotic killing of polymorphonuclear leukocytes is caused by quorum-sensing-controlled production of rhamnolipid by Pseudomonas aeruginosa. Microbiology. 2007;153:1329–1338
  80. Van Gennip M, Christensen LD, Alhede M, Phipps R, Jensen PØ, Christophersen L, et al. Inactivation of the rhlA gene in Pseudomonas aeruginosa prevents rhamnolipid production, disabling the protection against polymorphonuclear leukocytes. APMIS. 2009;117:537–546
  81. Alhede M, Bjarnsholt T, Jensen PØ, Phipps RK, Moser C, Christophersen L, et al. Pseudomonas aeruginosa recognizes and responds agressively to the presence of polymorphonuclear leukocytes. Microbiology. 2009;155:3500–3508
  82. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science. 1998;280:295–298
  83. Parsek MR, Greenberg EP. Sociomicrobiology: the connections between quorum sensing and biofilms. Trends Microbiol. 2005;13:27–33
  84. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 2003;22:3803–3815
  85. Givskov M, de Nys R, Manefield M, Gram L, Maximilien R, Eberl L, et al. Eukaryotic interference with homoserine lactone-mediated prokaryotic signalling. J Bacteriol. 1996;178:6618–6622
  86. Rasmussen TB, Bjarnsholt T, Skindersoe ME, Hentzer M, Kristoffersen P, Köte M, et al. Screening for quorum-sensing inhibitors (QSI) by use of a novel genetic system, the QSI selector. J Bacteriol. 2005;187:1799–1814
  87. Wu H, Song ZJ, Hentzer M, Andersen JB, Heydorn A, Mathee K, et al. Detection of N-acylhomoserine lactones in lung tissues of mice infected with Pseudomonas aeruginosa. Microbiology. 2000;146:2481–2493
  88. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for treatment of chronic bacterial infections. J Clin Invest. 2003;112:1300–1307
  89. Hoffmann N, Lee B, Hentzer M, Rasmussen TB, Song Z, Johansen HK, et al. Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr−/− mice. Antimicrob Agents Chemother. 2007;51:3677–3687
  90. Skindersøe ME, Alhede M, Phipps R, Yang L, Jensen PO, Rasmussen TB, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2008;52:3548–3663
  91. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomized trial. Thorax. 2002;57:212–216
  92. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet. 2002;360:978–984
  93. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003;290:1749–1756
  94. Hansen CR, Pressler T, Koch C, Høiby N. Long-term azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros. 2005;4:35–40
  95. Tramper-Stranders GA, Wolfs TFW, Fleer A, Kimpen JLL, van der Ent CK. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J. 2007;26:8–12
  96. Bjarnsholt T, Jensen PØ, Rasmussen TB, Christophersen L, Calun H, Hentzer M, et al. Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections. Microbiology. 2005;151:3873–3880
  97. Lee B, Haagensen JAJ, Ciofu O, Andersen JB, Høiby N, Molin S. Heterogeneity of biofilms formed by non-mucoid Pseudomonas aeruginosa isolates from patients with cystic fibrosis. J Clin Microbiol. 2005;43:5247–5255
  98. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322
  99. Stensballe J, Tvede M, Loorns D, Lippert FK, Dahl B, Tønnesen E, et al. Infection risk with nitrofurazone-impregnated urinary catheters in trauma patients. Ann Intern Med. 2007;147:285–293
  100. Reid G. Biofilms in infectious disease and on medical devices. Int J Antimicrob Agents. 1999;11:223–226
  101. Høiby N, Pedersen SS. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand. 1989;78:395–404
  102. Döring G, Høiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros. 2004;3:67–91
  103. Frederiksen B, Pressler T, Hansen A, Koch C, Høiby N. Effect of aerosolised rhDNase (Pulmozyme®) on pulmonary colonization in patients with cystic fibrosis. Acta Paediatr. 2006;95:1070–1074
  104. Baumann U, Stocklossa C, Greiner W, von der Schulenburg JM, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. J Cyst Fibros. 2003;2:84–90
  105. Frederiksen B, Koch C, Høiby N. The changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients, 1974–1995. Pediatr Pulmonol. 1999;28:159–166
  106. van Gennip M, Moser C, Christensen LD, Bjarnsholt T, Calum H, Jensen PØ, et al. Augmented effect of early antibiotic therapy in mice with experimental lung infections due to sequentially adapted mucoid strains of Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;64:1241–1250
  107. Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine. 2008;26:1011–1024
  108. Doring G, Conway SP, Heijerman HGM, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000;16:749–767
  109. Høiby N, Flensborg EW, Beck B, Friis B, Jacobsen L, Jacobsen SV. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis. Scand J Respir Dis. 1977;58:65–79
  110. Proesmans M, Balinska-Miskiewicz W, Dupont L, Bossuyt X, Verhaegen J, Høiby N, et al. Evaluating the ‘Leeds criteria’ for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur Respir J. 2006;27:937–943
  111. Frederiksen B, Lanng S, Koch C, Høiby N. Improved survival in the Danish cystic fibrosis centre: results of aggressive treatment. Pediatr Pulmonol. 1996;21:153–158
  112. Koch C, Hjelt K, Pedersen SS, Jensen ET, Jensen T, Lanng S, et al. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other β-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses. Rev Infect Dis. 1991;13(Suppl 7):S608–S611

PII: S0924-8579(10)00009-9

doi: 10.1016/j.ijantimicag.2009.12.011

International Journal of Antimicrobial Agents
Volume 35, Issue 4 , Pages 322-332 , April 2010

Article Tools

* Image Usage & Resolution